J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 8,490.00
+10.00 (0.12%)
At close: Jan 29, 2026
J2KBIO Revenue
J2KBIO had revenue of 8.56B KRW in the quarter ending September 30, 2025, with 31.49% growth. This brings the company's revenue in the last twelve months to 31.12B, down -10.32% year-over-year. In the year 2024, J2KBIO had annual revenue of 33.13B with 16.36% growth.
Revenue (ttm)
31.12B
Revenue Growth
-10.32%
P/S Ratio
1.60
Revenue / Employee
576.38M
Employees
54
Market Cap
49.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.13B | 4.66B | 16.36% |
| Dec 31, 2023 | 28.47B | 12.44B | 77.60% |
| Dec 31, 2022 | 16.03B | 1.81B | 12.75% |
| Dec 31, 2021 | 14.22B | 360.95M | 2.60% |
| Dec 31, 2020 | 13.86B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ark Solutions | 21.50B |
| PanGen Biotech | 15.27B |
| NGeneBio | 9.98B |
| MOA Life Plus | 9.80B |
| HLB Pep | 4.89B |
| EyeGene | 4.10B |
| SunBio,Inc. | 2.17B |
| SCM Lifescience | 1.54B |